Listen
FAMPYRA (fampridine) - Multiple sclerosis
Opinions on drugs -
Posted on
Apr 30 2025
Reason for request
Inscription
Summary of opinion
Favourable opinion for reimbursement in the indication for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
No clinical added value of the new bottle forms of FAMPYRA (fampridine) compared to the forms already available.
Clinical Benefit
| Low |
The clinical benefit of FAMPYRA (fampridine) is low in the MA indication. |
Clinical Added Value
| no clinical added value |
These medicinal products are range supplements that do not provide any clinical added value (CAV V) compared to the forms already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
